Treatment of Postural Orthostatic Tachycardia Syndrome (POTS)

Non-Pharmacological Foundation

The American College of Cardiology recommends increasing fluid intake to 2-3 liters of water or electrolyte-balanced fluid daily to expand plasma volume and maintain adequate blood volume 1, 2
Patients with POTS should consume 5-10 grams of dietary sodium daily through liberalized salt in food, which equals approximately 1-2 teaspoons of table salt added to meals 1, 2
Waist-high compression stockings or abdominal binders should be worn to reduce venous pooling in lower extremities and maintain central blood volume 1, 2
Elevating the head of the bed by 4-6 inches during sleep can help prevent nocturnal polyuria, maintain favorable fluid distribution, and promote chronic volume expansion 1, 2
Patients should start with recumbent exercise, such as rowing, swimming, or recumbent bike, to avoid upright posture that triggers symptoms, then gradually progress to upright exercise as tolerated 2

Propranolol is the initial pharmacologic choice for excessive sympathetic activity and tachycardia in hyperadrenergic POTS 2
Ivabradine 5 mg twice daily can be used as second-line treatment after propranolol failure, particularly when beta-blocker fatigue is problematic 2
Midodrine 2.5-10 mg three times daily provides direct alpha-1 agonist peripheral vasoconstriction, particularly effective for neuropathic POTS with impaired vasoconstriction during orthostatic stress 1, 2
Fludrocortisone 0.1-0.3 mg once daily stimulates renal sodium retention and expands fluid volume through mineralocorticoid-mediated volume expansion, working synergistically with salt loading 1, 2

Monitor for supine hypertension with vasoconstrictors like midodrine, especially in older males due to potential urinary outflow issues 1
Assess response to treatment by monitoring standing heart rate and symptom improvement, including peak symptom severity, time able to spend upright before needing to lie down, and cumulative hours able to spend upright per day 1
Avoid medications that inhibit norepinephrine reuptake in all POTS patients 1

For nausea/vomiting, use antiemetics and prokinetics, such as ondansetron, promethazine, and metoclopramide 3
For constipation, trial osmotic or stimulant laxatives, lubiprostone, guanylate cyclase-C agonists, prucalopride, or tenapanor 3
For diarrhea, use loperamide, bile acid sequestrants, eluxadoline, or 5-HT3 receptor antagonists 3
Avoid opiates, as they should not be used specifically to treat abdominal pain in these patients 3

Avoid norepinephrine reuptake inhibitors in all POTS patients because they can exacerbate the hyperadrenergic state that underlies many POTS subtypes. 4
Diuretics, vasodilators, venodilators, negative chronotropes, and sedatives should be avoided as they have been linked to worsening syncope and orthostatic symptoms, especially in older individuals. 4
Reducing or withdrawing drugs that may cause hypotension is beneficial for patients with syncope, since such agents can compound orthostatic intolerance. 4

When using vasoconstrictors such as midodrine, monitor for supine hypertension, particularly in older male patients. 4
Assess treatment response by tracking standing heart rate, symptom improvement, duration of upright tolerance, and total daily upright time to gauge efficacy and safety of medication adjustments. 4
Close supervision is required during medication changes because of the risk of precipitating supine hypertension or cardiac arrhythmias. 4

Ketotifen is not listed among medications to avoid in comprehensive POTS guidelines, and its pharmacologic profile (mast cell stabilization and H1 antihistaxis) does not overlap with drug classes known to worsen POTS. Consequently, there is no clinical basis to withhold ketotifen from POTS patients who have an independent indication for mast cell stabilization. 4